Literature DB >> 33567200

Atezolizumab for PD-L1-Selected Patients with NSCLC.

Nobuyuki Horita1, Nobuhiko Fukuda1, Takeshi Kaneko1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33567200     DOI: 10.1056/NEJMc2032432

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  A Problematic Biomarker Trial Design.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 13.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.